| Automatic and quantitative measurement of protein-protein colocalization in live cells SV Costes, D Daelemans, EH Cho, Z Dobbin, G Pavlakis, S Lockett Biophysical journal 86 (6), 3993-4003, 2004 | 1543 | 2004 |
| Stem cell pathways contribute to clinical chemoresistance in ovarian cancer AD Steg, KS Bevis, AA Katre, A Ziebarth, ZC Dobbin, RD Alvarez, ... Clinical cancer research 18 (3), 869-881, 2012 | 404 | 2012 |
| The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer ZC Dobbin, CN Landen International journal of molecular sciences 14 (4), 8213-8227, 2013 | 203 | 2013 |
| Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer ZC Dobbin, AA Katre, AD Steg, BK Erickson, MM Shah, RD Alvarez, ... Oncotarget 5 (18), 8750, 2014 | 143 | 2014 |
| Smoothened antagonists reverse taxane resistance in ovarian cancer AD Steg, AA Katre, KS Bevis, A Ziebarth, ZC Dobbin, MM Shah, ... Molecular cancer therapeutics 11 (7), 1587-1597, 2012 | 104 | 2012 |
| SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK H Li, Q Cai, H Wu, V Vathipadiekal, ZC Dobbin, T Li, X Hua, CN Landen, ... Molecular Cancer Research 10 (11), 1462-1472, 2012 | 84 | 2012 |
| Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer AJ Ziebarth, S Nowsheen, AD Steg, MM Shah, AA Katre, ZC Dobbin, ... Clinical cancer research 19 (1), 170-182, 2013 | 77 | 2013 |
| Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK) AN Shajahan, ZC Dobbin, FE Hickman, S Dakshanamurthy, R Clarke Journal of Biological Chemistry 287 (21), 17682-17692, 2012 | 69 | 2012 |
| Ovarian and cervical cancer patient derived xenografts: The past, present, and future JD Boone, ZC Dobbin, JM Straughn Jr, DJ Buchsbaum Gynecologic oncology 138 (2), 486-491, 2015 | 54 | 2015 |
| Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma RC Arend, AI Londoño, AM Montgomery, HJ Smith, ZC Dobbin, AA Katre, ... Molecular Cancer Research 16 (5), 813-824, 2018 | 53 | 2018 |
| An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer MM Shah, ZC Dobbin, S Nowsheen, M Wielgos, AA Katre, RD Alvarez, ... Gynecologic oncology 134 (2), 331-337, 2014 | 53 | 2014 |
| Targeting RNA-polymerase I in both chemosensitive and chemoresistant populations in epithelial ovarian cancer R Cornelison, ZC Dobbin, AA Katre, DH Jeong, Y Zhang, D Chen, ... Clinical Cancer Research 23 (21), 6529-6540, 2017 | 52 | 2017 |
| Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer BK Erickson, I Kinde, ZC Dobbin, Y Wang, JY Martin, RD Alvarez, ... Obstetrics & Gynecology 124 (5), 881-885, 2014 | 52 | 2014 |
| Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer AD Steg, MR Burke, HM Amm, AA Katre, ZC Dobbin, DH Jeong, ... Oncotarget 5 (16), 7065, 2014 | 34 | 2014 |
| Isolation and characterization of potential cancer stem cells from solid human tumors—potential applications ZC Dobbin, CN Landen Current Protocols in Pharmacology 63 (1), 14.28. 1-14.28. 19, 2013 | 34 | 2013 |
| Targeting RNA-polymerase I using CX-5461 as a mechanism for treating chemotherapy resistant epithelial ovarian cancer R Cornelison, ZC Dobbin, AA Katre, DH Jeong, Y Petrova, DC Llaneza, ... Cancer Research 76 (14_Supplement), 324-324, 2016 | 4 | 2016 |
| Inhibition of autophagy potentiates cytotoxicity of CX-5461 treatment in chemoresistant epithelial ovarian cancer R Cornelison, DC Llaneza, Y Petrova, ZC Dobbin, DA Schneider, ... Cancer Research 77 (13_Supplement), 3211-3211, 2017 | 2 | 2017 |
| Use of an optimized primary ovarian cancer xenograft model to mimic patient tumor biology and heterogeneity. ZC Dobbin, AA Katre, A Ziebarth, M Shah, AD Steg, RD Alvarez, ... Journal of Clinical Oncology 30 (15_suppl), 5036-5036, 2012 | 2 | 2012 |
| Abstract A58: An ovarian patient-derived xenograft model to identify the chemoresistant population ZC Dobbin, AK Katre, MM Shah, BK Erickson, H Chen, RD Alvarez, ... Clinical Cancer Research 19 (19_Supplement), A58-A58, 2013 | 1 | 2013 |
| Towards personalized PARP therapy: XRT-induced Rad51 predicts re-sponse to ABT-888 in ovarian cancer M Shah, S Nowsheen, A Katre, Z Dobbin, B Erickson, R Alvarez, ... Gynecologic Oncology 130 (1), e35, 2013 | 1 | 2013 |
